BPH Groups Research Articles

Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer

In differential diagnosis of BPH and early stages prostate cancer (PC), PSA-density (PSAD) was evaluated in 63 cases with BPH and 82 cases of PC (stage A: 8, B: 17, C: 17, D: 40). Serum PSA values were determined by MARKIT-F PA, and prostate volume was calculated by transabdominal ultrasonography, in which every glands including peripheral zone was visualized in the transverse and sagittal planes, and predicted prostate volume was calculated by three dimension (a x b x c x 0.52). PSAD was determined by serum PSA divided by prostate volume. PSAD values were 0.106 +/- 0.006 (mean +/- SD) in BPH, 0.538 +/- 0.094 in stage A and B of PC, and 2.973 +/- 0.764 in all PC cases. There was a statistical significance (p < 0.005) between BPH and each other groups of PC by student's t-test. In using 0.208 (mean +/- 2 SD of PSAD in BPH group) as a cut-off value, the detection sensitivity was 84% in stage A and B of PC and the specificity was 97% using BPH groups as a control, therefore the efficacy was 93%. In 18 out of 19 cases with BPH having PSA values more than 3.6 ng/ml (false positive group), PSAD values were less than 0.208. PSAD is suggested to be a useful tool for differential diagnosis of BPH and early stages of PC.

Two-Site Monoclonal Antibody-Based Immunoradiometric Assay for Measuring Prostate Secretory Protein in Serum

We developed a double-determinant immunoradiometric assay for measuring serum prostate secretory protein (PSP), using monoclonal antibodies (MAb) against two different epitopes: MAb PSP-19 was the capture antibody and MAb PSP-6 was the tracer antibody. Assay sensitivity was 0.1 microgram/L. Analytical recovery of PSP was 93.5-104.6%, whereas the intra- and interassay mean CVs were 4.2% and 6.9%, respectively. In 92 normal men, ages greater than 50 years, the mean PSP concentration was 5.7 micrograms/L, with 10 (10.9%) men having concentrations greater than 10 micrograms/L. In contrast, 20 of 49 (40.8%) patients with benign prostate hyperplasia (BPH; mean PSP concentration 9.4 micrograms/L) and 46 of 100 (46%) patients with prostate cancer (mean PSP concentration 22.2 micrograms/L) had PSP concentrations greater than 10 micrograms/L. Mean serum PSP concentrations of the BPH (P less than 0.05) and prostate cancer (P less than 0.01) groups were significantly different from those of age-matched normal men. In a small group of patients, serial PSP concentrations correlated with the clinical course during therapy. Thus, PSP may be a useful marker for evaluating patients with prostate cancer.